Agios Pharmaceuticals, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021; the filing was signed February 24, 2022. Unless noted, financial figures are in U.S. dollars. Agios is a biopharmaceutical company focused on small-molecule treatments for genetically defined diseases. Following its March 2021 oncology-business sale, its principal focus is the PYRUKYND (mitapivat) and AG-946 programs.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net income (loss) | $1,604.7 million | $(327.4) million |
| Continuing-operations net loss | $(356.5) million | $(329.3) million |
| Research and development expense | $257.0 million | $220.8 million |
| Selling, general and administrative expense | $121.4 million | $115.1 million |
| Cash used in operating activities, continuing operations | $314.1 million | $243.9 million |
- FY2021 reported net income primarily reflects the sale of the oncology business: the company recorded a $1,989.1 million pretax gain and $1,976.3 million after-tax gain on sale. Net income from discontinued operations was $1,961.2 million. These items do not indicate recurring operating profitability.
- Fourth-quarter 2021 continuing-operations loss was $98.6 million; net loss was $94.6 million, or $1.74 per share. Discontinued operations contributed $4.0 million of net income for the quarter.
- At year-end, cash and cash equivalents were $203.1 million and marketable securities were $1,083.3 million, totaling $1,286.4 million. Total assets were $1,437.7 million; total liabilities were $145.8 million; stockholders’ equity was $1,292.0 million.
- The filing reports no conventional borrowings. Lease liabilities totaled $96.5 million, including $10.8 million current and $85.7 million non-current. Disclosed contractual obligations also include operating leases, manufacturing and service arrangements.
- Cash from investing activities was $1,248.8 million, largely reflecting approximately $1.8 billion of sale proceeds, partly offset by investment purchases. Financing activities used $765.8 million, primarily for $802.5 million of share repurchases. No gross margin or recurring continuing-operations product revenue figure is clearly provided.
Material changes versus prior period
- The oncology business—including TIBSOVO, vorasidenib and related programs—was sold to Servier on March 31, 2021. Historical oncology results are presented as discontinued operations, so reported net income and cash-flow comparisons are substantially affected by the transaction.
- Continuing-operations net loss widened by $27.2 million from 2020, and continuing-operations operating cash use increased by $70.1 million. R&D expense rose $36.2 million, mainly from PYRUKYND trial activity and other research programs; SG&A increased $6.3 million, including commercial-launch preparation.
- Agios repurchased 16.2 million shares for $802.5 million during 2021 under a $1.2 billion authorization. Repurchases were paused as the company prioritized pipeline investment and potential business-development opportunities.
Outlook, commentary and key risks
- After year-end, on February 17, 2022, the FDA approved PYRUKYND for hemolytic anemia in adults with PK deficiency. Agios expected a U.S. commercial launch in Q1 2022. Its EU marketing application remained under review.
- Management stated that year-end cash, cash equivalents and marketable securities were expected to fund the operating plan through major catalysts and cash-flow positivity without additional equity; the financial statements also state resources were expected to fund current operations for at least the following 12 months. These are forward-looking estimates, not guarantees.
- Planned development includes phase 3 PYRUKYND trials in thalassemia, a phase 2/3 SCD program, planned pediatric PK-deficiency trials, and AG-946 studies in SCD and lower-risk MDS. Enrollment, trial outcomes, approvals and commercialization timing remain uncertain.
- Servier may owe a $200 million milestone if vorasidenib receives specified FDA approval before January 1, 2027. Agios is also entitled to 5% royalties on U.S. TIBSOVO net sales and 15% on U.S. vorasidenib net sales, subject to contractual terms; the milestone and future royalties are uncertain.
- Principal risks include successful PYRUKYND launch and reimbursement, clinical and regulatory setbacks, patient enrollment delays, competition, dependence on third-party manufacturers, intellectual-property protection, and the company’s reduced diversification after the oncology sale. COVID-19 had disrupted some clinical operations; no significant direct financial or supply-chain impact was reported through year-end. The filing reported no material legal proceedings.
Investor facts to verify
- PYRUKYND launch progress, prescription uptake, payer coverage, pricing and any emerging safety findings.
- EU review outcome and progress, enrollment and results for PYRUKYND’s additional-indication and pediatric trials, and AG-946 development milestones.
- Quarterly continuing-operations cash burn and liquidity against management’s stated runway and cash-flow-positivity objective.
- Servier royalty receipts and whether the vorasidenib milestone becomes achievable; confirm the effects of the share-repurchase pause on capital allocation.
- Manufacturing continuity and patent protection, particularly given reliance on third parties and the disclosed absence of redundant drug-product supply arrangements.